Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
GNMK > SEC Filings for GNMK > Form 8-K on 14-Aug-2013All Recent SEC Filings

Show all filings for GENMARK DIAGNOSTICS, INC.



Entry into a Material Definitive Agreement, Other Events, Financial Sta

Item 1.01 Entry into a Material Definitive Agreement.

On August 13, 2013, GenMark Diagnostics, Inc., a Delaware corporation (the "Company"), entered into an Underwriting Agreement (the "Underwriting Agreement") with J.P. Morgan Securities LLC acting as sole book-running manager and as representative of the underwriters named therein (the "Underwriters") relating to the issuance and sale of 7,622,000 shares of the Company's common stock, par value $0.0001 per share (the "Offering"). The price to the public in the Offering is $9.84 per share, and the Underwriters have agreed to purchase the shares from the Company pursuant to the Underwriting Agreement at a price of $9.2496 per share. Under the terms of the Underwriting Agreement, the Company has granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 1,143,000 shares. The net proceeds to the Company from the Offering are expected to be approximately $70.1 million, after deducting underwriting discounts and commissions and estimated Offering expenses payable by the Company, assuming no exercise by the Underwriters of its option to purchase additional shares of Common Stock. The transactions contemplated by the Underwriting Agreement are expected to close on August 19, 2013, subject to the satisfaction of customary closing conditions.

The Offering was made pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-187371), as supplemented by a preliminary and final prospectus supplement thereunder, filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the "Securities Act").

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this Current Report and is incorporated herein by reference. The foregoing description of the terms of the Underwriting Agreement is qualified in its entirety by the Underwriting Agreement.

The legal opinion, including the related consent, of DLA Piper LLP (US) relating to the legality of the issuance and sale of the shares of the Company's common stock in the Offering is filed as Exhibit 5.1 to this Current Report.

This Current Report contains forward-looking statements that involve risk and uncertainties, such as statements related to the anticipated closing of the Offering and the amount of net proceeds expected from the Offering. The risks and uncertainties involved include the Company's ability to satisfy certain conditions to closing on a timely basis or at all, as well as other risks detailed from time to time in the Company's Securities and Exchange Commission filings.

Item 8.01 Other Events.

On August 12, 2013, the Company issued a press release announcing that it had commenced the Offering, and on August 13, 2013, the Company issued a press release announcing that it had priced the Offering. Copies of these press releases are attached as Exhibits 99.1 and 99.2 hereto, respectively.

Item 9.01 Financial Statements and Exhibits.

(d) The following exhibits are filed with this Current Report:

  No.                                     Description

 1.1         Underwriting Agreement, dated August 13, 2013, between GenMark
             Diagnostics, Inc. and J.P. Morgan Securities LLC

 5.1         Opinion and Consent of DLA Piper LLP (US)

23.1         Consent of DLA Piper LLP (US) (included in Exhibit 5.1)

99.1         Press Release, dated August 12, 2013, titled "GenMark Diagnostics
             Announces Proposed Public Offering of Common Stock"

99.2         Press Release, dated August 13, 2013, titled "GenMark Diagnostics
             Prices Public Offering of Common Stock"

  Add GNMK to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for GNMK - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.